Stifel says Outset TabloCart with Prefiltration approval earlier than expected

Stifel notes the FDA announced approval for Outset’s TabloCart with Prefiltration accessory with a “substantially-equivalent” decision, telling investors that the approval came “a touch earlier-than-anticipated” and is “clearly-positive news.” TabloCart With Prefiltration is an accessory for Outset’s Tablo hemodialysis system designed to enhance Tablo’s water filtration capabilities in areas with poor water quality, notes the analyst, who is “inclined to view today’s announcement as a clear-cut positive signal increasing our optimism about 2H24 Consensus numbers and our positive outlook for Outset’s 2025 and beyond sales reacceleration potential.” The firm has a Buy rating and $6 price target on Outset Medical shares.